Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

Indaptus Therapeutics (INDP) announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion ...

Initial data indicate that Decoy20 at the 30 million cell dose was generally well-tolerated, with a favorable safety profile and promising early signs of clinical benefit, including some patients ...

Indaptus Therapeutics announced significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort. Initial clinical data shows promising ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

The latest results from the weekly dosing cohort show that Decoy20 is generally well-tolerated and has led to immune cell trafficking, a key process in effective anticancer immune response.

(RTTNews) - Indaptus Therapeutics, Inc.(INDP), Monday announced the initiation of a new expansion arm in its Phase 1b/2 clinical trial to evaluate the combination of Decoy20 with BeiGene's PD-1 ...

The INDP-D101 trial will now admit Canadian patients under the existing protocol, which includes weekly dosing of Decoy20. Furthermore, Indaptus intends to propose an amendment to Health Canada to ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics ...

PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body's ability to fight cancer. Combining ...